Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis;…
$GMAB Genmab, AbbVie Announce Data From Phase 3 EPCORE DLBCL-2 Study Of Epcoritamab Demonstrates Reduction In Disease Progression, Death By 51% For Large B-Cell Lymphoma Benzinga Newsdesk (Benzinga Newswire) Genmab A/S (NASDAQ:GMAB) and AbbVie (NYSE:ABBV) announced today…
$GMAB call on tape in this Bio https://t.co/cJkk50rYQK
11 analysts rate GMAB Buy on consensus.
Consensus price target: $45.04 (+2.85% upside from $43.79)
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $3.72B | +15.38% | $963.76M |
| 2024 | $3.23B | +30.67% | $1.18B |
| 2023 | $2.47B | +13.57% | $652.32M |
Stock data for GMAB: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics